A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Study identifier:D7130C00001

ClinicalTrials.gov identifier:NCT06115967

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy participants

Medical condition

Rheumatoid Arthritis

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6912, Placebo

Sex

All

Estimated Enrollment

64

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 15 Nov 2023
Estimated Primary Completion Date: 08 Jul 2025
Estimated Study Completion Date: 08 Jul 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria